Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Bayer, Novartis Lose Case Seeking to End NHS Use of Roche’s Avastin

By Catherine Sbeglia | September 24, 2018

Novartis and Bayer’s case against National Health Services in Northern England has been dismissed by the U.K. High Court. The court ruled that NHS can continue to use Roche’s Avastin (bevacizumab) for the treatment of wet age-related macular degeneration (AMD) despite Novartis and Bayer’s claim that Avastin should not be used by NHS because it is not licensed for this particular indication. Bayer and Novartis market the AMD therapies Eylea (aflibercept) and Lucentis (ranibizumab), respectively.

The Judge rejected the companies’ argument, stating that treating clinicians can lawfully choose Avastin for ophthalmic use on grounds of cost. Avastin, which costs only $37 per injection for use in wet AMD, is a more appealing option for patients when compared to Lucentis, which costs $727 per injection, and Eylea, which costs $1076 per injection.

Chief Executive Officer of NHS South Tyneside CCG, David Hambleton described the ruling as “a victory for common sense over commercial interested.” He added that the decision will save “in excess of 13.5 million pounds ($17.7 million) per year for the 12 CCGs involved in this litigation alone, and hundreds of millions of pounds across the country.”

A Novartis spokesperson, however, believes the ruling undermines the established framework for such matters. “The policy undermines the well-established legal and regulatory framework that is there to protect both patients’ safety and to ensure health care professionals can prescribe with confidence.”  

Novartis does not appear to be alone in this opinion. Sheuli Porkess, deputy chief scientific advisor to The Association of the British Pharmaceutical Industry, also noted that the ruling jeopardizes clarity for both patients and doctors.

Hambleton, however, notes the court’s decision could result in a rethink for U.K regulartory agencies, which, he states, will “now […] have the option of allowing the use of so-called ‘off-label’ drugs.”

(Source: BBC News)

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards